Free Trial

Rocket Pharmaceuticals (RCKT) News Today

$22.68
-0.31 (-1.35%)
(As of 06/7/2024 ET)
Sectoral Asset Management Inc. Sells 214,750 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Sectoral Asset Management Inc. cut its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 94.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,280 shares of the biotechnology company's
TD Asset Management Inc Buys 42,834 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
TD Asset Management Inc raised its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 38.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 154,864 shares of the biotechn
Rocket Pharmaceuticals, Inc. to Post Q1 2025 Earnings of ($0.64) Per Share, William Blair Forecasts (NASDAQ:RCKT)
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Equities research analysts at William Blair reduced their Q1 2025 earnings per share estimates for shares of Rocket Pharmaceuticals in a report issued on Monday, June 3rd. William Blair analyst S. Corwin now expects that the biotechnology
Rocket Pharmaceuticals' (RCKT) Outperform Rating Reiterated at William Blair
William Blair reaffirmed an "outperform" rating on shares of Rocket Pharmaceuticals in a research note on Monday.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP lowered its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 21.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,047,941 shares of the biotec
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Charles Schwab Investment Management Inc.
Charles Schwab Investment Management Inc. increased its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 12.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 525,452 shares o
Rocket Park assault leads to arrest
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Franklin Resources Inc.
Franklin Resources Inc. lifted its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 60.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,072,910 shares of the biotechnology company's stock after pu
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Westfield Capital Management Co. LP
Westfield Capital Management Co. LP trimmed its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 6.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,941,859 shares of the biote
Assenagon Asset Management S.A. Trims Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Assenagon Asset Management S.A. lessened its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 88.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 80,726 shares of the biotec
Q2 2024 EPS Estimates for Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Decreased by Leerink Partnrs
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Leerink Partnrs reduced their Q2 2024 earnings per share estimates for Rocket Pharmaceuticals in a research note issued on Tuesday, May 7th. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earnings
Rocket Pharmaceuticals (NASDAQ:RCKT) Releases Earnings Results, Beats Estimates By $0.01 EPS
Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) posted its earnings results on Monday. The biotechnology company reported ($0.66) earnings per share for the quarter, topping analysts' consensus estimates of ($0.67) by $0.01. During the same period in the previous year, the company posted ($0.73) EPS.
Needham & Company LLC Reaffirms Buy Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)
Needham & Company LLC restated a "buy" rating and issued a $53.00 target price on shares of Rocket Pharmaceuticals in a research note on Tuesday.
Russell Investments Group Ltd. Has $19.45 Million Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Russell Investments Group Ltd. decreased its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 10.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 648,946 shares of the bio
Rocket Pharmaceuticals Upgraded to Buy: Here's Why
Rocket Pharmaceuticals, Inc. (RCKT)
Get Rocket Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.

Top 5 AI Stocks to Buy for 2024 (Ad)

The electric vehicle boom is accelerating – and fast.

Click to View The 5 Best AI Stocks to Invest In

RCKT Media Mentions By Week

RCKT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RCKT
News Sentiment

0.29

0.73

Average
Medical
News Sentiment

RCKT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RCKT Articles
This Week

11

8

RCKT Articles
Average Week

Get Rocket Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:RCKT) was last updated on 6/8/2024 by MarketBeat.com Staff

From Our Partners